Lilly Tells Physicians To Have Patience With Strattera
This article was originally published in The Pink Sheet Daily
Executive Summary
The company's efforts to re-energize the brand include an increased focus on atomoxetine's delayed onset of action in its professional detailing. Lilly also expects increased penetration of the adult ADD market to help boost Strattera's market share.
You may also be interested in...
ADHD Market Hurt By Safety Concerns, Lilly Says
Strattera marketer says that label change and withdrawal of Shire's Adderall XR in Canada has slowed the growth of the attention deficit/hyperactivity disorder market. Lilly will focus on consumers with new DTC ad designed to encourage adult patients to seek treatment.
ADHD Market Hurt By Safety Concerns, Lilly Says
Strattera marketer says that label change and withdrawal of Shire's Adderall XR in Canada has slowed the growth of the attention deficit/hyperactivity disorder market. Lilly will focus on consumers with new DTC ad designed to encourage adult patients to seek treatment.
Strattera Labeling Adds Bolded Warning For Severe Liver Injury
Lilly revises labeling following two cases of severe liver injury attributed to the attention deficit/hyperactivity disorder treatment. The company plans to issue a "Dear Health Care Professional" letter Jan. 3.